EA200501549A1 - Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца - Google Patents

Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца

Info

Publication number
EA200501549A1
EA200501549A1 EA200501549A EA200501549A EA200501549A1 EA 200501549 A1 EA200501549 A1 EA 200501549A1 EA 200501549 A EA200501549 A EA 200501549A EA 200501549 A EA200501549 A EA 200501549A EA 200501549 A1 EA200501549 A1 EA 200501549A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heart disease
inhibitor
prevention
treating
treatment
Prior art date
Application number
EA200501549A
Other languages
English (en)
Other versions
EA010180B1 (ru
Inventor
Чарльз Динарелло
Бенджамин Померантц
Леонид Резников
Альден Харкен
Йоланд Шватшко
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Резеч Системз Арс Холдинг Н. В. filed Critical Апплайд Резеч Системз Арс Холдинг Н. В.
Publication of EA200501549A1 publication Critical patent/EA200501549A1/ru
Publication of EA010180B1 publication Critical patent/EA010180B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к применению экспрессирующего вектора, содержащего последовательность, кодирующую ингибитор IL-18, для приготовления лекарственного средства для лечения и/или профилактики заболевания сердца, в частности ишемической болезни сердца. Рассматривается также способ лечения заболевания сердца, предусматривающий введение нуждающемуся хозяину эффективного ингибирующего количества ингибитора IL-18.
EA200501549A 2001-01-29 2002-01-28 Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии EA010180B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29

Publications (2)

Publication Number Publication Date
EA200501549A1 true EA200501549A1 (ru) 2006-04-28
EA010180B1 EA010180B1 (ru) 2008-06-30

Family

ID=8176323

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200300844A EA006767B1 (ru) 2001-01-29 2002-01-28 Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики заболевания сердца
EA200501549A EA010180B1 (ru) 2001-01-29 2002-01-28 Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200300844A EA006767B1 (ru) 2001-01-29 2002-01-28 Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики заболевания сердца

Country Status (32)

Country Link
US (1) US20040234523A1 (ru)
EP (1) EP1355668B1 (ru)
JP (2) JP4860897B2 (ru)
KR (1) KR100857376B1 (ru)
CN (1) CN1326562C (ru)
AR (1) AR032422A1 (ru)
AT (1) ATE380558T1 (ru)
BG (1) BG66483B1 (ru)
BR (1) BR0206819A (ru)
CA (1) CA2435466C (ru)
CY (1) CY1107203T1 (ru)
CZ (1) CZ305653B6 (ru)
DE (1) DE60224004T2 (ru)
DK (1) DK1355668T3 (ru)
EA (2) EA006767B1 (ru)
EE (1) EE05534B1 (ru)
ES (1) ES2295332T3 (ru)
HK (1) HK1062810A1 (ru)
HR (1) HRP20030609A2 (ru)
HU (1) HU229164B1 (ru)
IL (2) IL157024A0 (ru)
ME (1) ME00549B (ru)
MX (1) MXPA03006776A (ru)
NO (1) NO331083B1 (ru)
PL (1) PL213568B1 (ru)
PT (1) PT1355668E (ru)
RS (1) RS51125B (ru)
SI (1) SI1355668T1 (ru)
SK (1) SK287620B6 (ru)
UA (1) UA80676C2 (ru)
WO (1) WO2002060479A1 (ru)
ZA (1) ZA200305439B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335336B (ru) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
EP1331943A4 (en) 2000-10-11 2005-01-26 Viron Therapeutics Inc NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNOMODULATION
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
PL1891088T3 (pl) 2005-06-10 2012-03-30 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
AU2008324814B2 (en) * 2007-11-05 2013-05-16 Solventum Intellectual Properties Company Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MX2016002719A (es) * 2013-09-05 2016-09-06 Ab2 Bio Sa Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
MY194040A (en) 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
ATE310528T1 (de) * 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
DE69736984T2 (de) * 1996-12-06 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des interleukin-1-beta konvertierenden enzyms
CA2282845A1 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
AU3876600A (en) * 1999-03-16 2000-10-04 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
AU4213500A (en) * 1999-04-09 2000-11-14 Cytovia, Inc. Caspase inhibitors and the use thereof
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
TWI335336B (ru) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
UA87658C2 (ru) * 2000-05-05 2009-08-10 Апплайд Резеч Системз Арс Холдинг Н.В. Применение іl-18 как диагностического маркера сердечной недостаточности
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CA2435466A1 (en) 2002-08-08
HU229164B1 (en) 2013-09-30
NO20033228D0 (no) 2003-07-16
PL213568B1 (pl) 2013-03-29
CN1326562C (zh) 2007-07-18
HUP0303306A3 (en) 2005-12-28
AR032422A1 (es) 2003-11-05
NO331083B1 (no) 2011-10-03
DE60224004T2 (de) 2009-07-23
NO20033228L (no) 2003-09-26
ME00549B (me) 2011-10-10
JP4860897B2 (ja) 2012-01-25
ZA200305439B (en) 2004-07-15
BG66483B1 (bg) 2015-03-31
WO2002060479A1 (en) 2002-08-08
ES2295332T3 (es) 2008-04-16
HK1062810A1 (en) 2004-11-26
ATE380558T1 (de) 2007-12-15
EA010180B1 (ru) 2008-06-30
EP1355668A1 (en) 2003-10-29
PT1355668E (pt) 2008-01-04
IL157024A (en) 2014-02-27
BG108128A (bg) 2004-11-30
MXPA03006776A (es) 2003-10-24
EE200300328A (et) 2003-10-15
JP2004522748A (ja) 2004-07-29
UA80676C2 (en) 2007-10-25
CN1499982A (zh) 2004-05-26
EP1355668B1 (en) 2007-12-12
DE60224004D1 (de) 2008-01-24
JP2009102354A (ja) 2009-05-14
PL366802A1 (en) 2005-02-07
SI1355668T1 (sl) 2008-06-30
CA2435466C (en) 2012-04-03
US20040234523A1 (en) 2004-11-25
RS51125B (sr) 2010-10-31
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
CZ305653B6 (cs) 2016-01-27
EA200300844A1 (ru) 2003-12-25
KR100857376B1 (ko) 2008-09-05
CZ20032335A3 (en) 2004-07-14
HRP20030609A2 (en) 2005-06-30
BR0206819A (pt) 2004-02-03
IL157024A0 (en) 2004-02-08
EE05534B1 (et) 2012-04-16
SK10892003A3 (sk) 2004-02-03
HUP0303306A2 (hu) 2004-01-28
YU57803A (sh) 2006-05-25
DK1355668T3 (da) 2008-05-05
EA006767B1 (ru) 2006-04-28
CY1107203T1 (el) 2012-11-21

Similar Documents

Publication Publication Date Title
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
EA200401240A1 (ru) Применение ингибиторов il-18 для лечения и/или профилактики заболеваний периферических сосудов
DE60101265D1 (de) Behandlung von augenschmerzen
WO2002002518A3 (en) Compounds to treat alzheimer's disease
WO2002002520A3 (en) Compounds to treat alzheimer's disease
GB0223040D0 (en) Therapeutic compounds
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60115433D1 (de) Verfahren zur behandlung von chronischen geschwüren
TW200505473A (en) Compositions and methods for treatment of psoriasis
MXPA04003773A (es) Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento.
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
ATE270110T1 (de) Arzneimittel enthaltend tissue inhibitor of metalloproteinases-2 (timp-2) als osteoanabol wirksame substanz
SE0100873D0 (sv) Method of treatment
DE60108775T8 (de) Methode zur behandlung von schlaganfall

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MK4A Patent expired

Designated state(s): RU